Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Calithera Biosciences Inc.
Headquarters: South San Francisco, CA, United States of America
Website: N/A
Year Founded: 2010
Status: Out of Business
BioCentury | May 9, 2024
Management Tracks
Meyrick succeeding CMO Harris at radiopharma ITM
Plus: ALX hires Dillon and updates from Obsidian, YS and more
BioCentury | Mar 28, 2023
Management Tracks
Calithera’s Kuriakose to head oncology at Terns
Plus: Christine Foster named CBO at hC, and updates from Meliora, Seismic and ClavystBio
BioCentury | Jan 11, 2023
Deals
Jan. 10 Quick Takes: AbbVie taps Anima for mRNA therapeutics
Plus updates from Alto, Union, AskBio-Recode, Phathom and more
BioCentury | Nov 22, 2021
Management Tracks
Mallik resigns as CEO from Rafael
Plus: Connect, Fog, Elucida and Advanz
BioCentury | Nov 6, 2021
Deals
Nov. 5 Quick Takes: $103M raise to support bit.bio’s cell coding tech
Plus Alphabet launches digital biology venture, IO Biotech’s IPO, setbacks for Deciphera, Calithera and more
BioCentury | Nov 6, 2021
Management Tracks
Twyman becomes chief commercial officer at Inovio
Plus: Pharmaron, Calithera, T2 and more
BioCentury | Oct 20, 2021
Deals
Quick Takes: Singapore’s Cerecin raises $40M from enlarged syndicate
Crinetics spins out radiotherapeutics company, IO Biotech, Calithera, Sana and more
BioCentury | May 17, 2021
Deals
May 17 Quick Takes: Antengene adds CD73 inhibitor to pipeline via Calithera deal; plus Aadi, Apellis, Charles River-Vigene, FDA and Sanofi-GSK
Seven months after its $360 million IPO on the Hong Kong stock exchange, Shanghai-based Antengene Corp. Ltd. (HKEX:6996) is building out its pipeline with exclusive, worldwide development and
BioCentury | Apr 22, 2021
Management Tracks
Ceesay joins Coles’ Cerevel as president; plus updates from Replimune, Perceptive, Antiva, Vera, Patient Square, Zymeworks and more
BioCentury | Jan 5, 2021
Deals
Jan. 4 Quick Takes: Delay for FDA sinks Celgene CVR; plus NASDAQ updates for Clene, Gracell; a Provention PDUFA and more
Strike one, Celgene CVR is outBristol Myers Squibb Co. (NYSE:BMY) said a potential $6.8 billion contingent value right issued in the pharma’s $74 billion acquisition of Celgene Corp. in 2019
Items per page:
1 - 10 of 69